These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 15147461

  • 21. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
    Venken K, Hellings N, Hensen K, Rummens JL, Medaer R, D'hooghe MB, Dubois B, Raus J, Stinissen P.
    J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
    [Abstract] [Full Text] [Related]

  • 22. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis.
    Salama HH, Hong J, Zang YC, El-Mongui A, Zhang J.
    Brain; 2003 Dec; 126(Pt 12):2638-47. PubMed ID: 12937077
    [Abstract] [Full Text] [Related]

  • 23. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Serum levels of several chemokines in patients with rheumatoid arthritis].
    Wu HX, Zhang Y, Zhu YL.
    Zhonghua Yi Xue Za Zhi; 2005 Mar 02; 85(8):534-7. PubMed ID: 15949333
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing-remitting multiple sclerosis patients.
    Kalinowska-Łyszczarz A, Szczuciński A, Pawlak MA, Losy J.
    J Neurol Sci; 2011 Jan 15; 300(1-2):81-5. PubMed ID: 20947098
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Cladribine tablets' potential in multiple: sclerosis treatment.
    Costello K, Sipe JC.
    J Neurosci Nurs; 2008 Oct 15; 40(5):275-80. PubMed ID: 18856248
    [Abstract] [Full Text] [Related]

  • 33. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T, Torkildsen Ø, Myhr KM.
    Expert Opin Pharmacother; 2017 Oct 15; 18(15):1627-1635. PubMed ID: 28858531
    [Abstract] [Full Text] [Related]

  • 34. Chemokines Rantes and interleukin-8 in the perinatal period: changes in serum concentrations.
    Malamitsi-Puchner A, Sarandakou A, Tziotis J, Economou E, Protonotariou E, Rigopoulou O.
    Am J Perinatol; 2004 May 15; 21(4):235-40. PubMed ID: 15168323
    [Abstract] [Full Text] [Related]

  • 35. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M, Wiendl H.
    J Neuroimmunol; 2005 Feb 15; 159(1-2):155-64. PubMed ID: 15652415
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b.
    Iarlori C, Reale M, Lugaresi A, De Luca G, Bonanni L, Di Iorio A, Feliciani C, Conti P, Gambi D.
    J Neuroimmunol; 2000 Jul 10; 107(1):100-7. PubMed ID: 10808056
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.